| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Human A3 adenosine receptor (A3AR).
|
|---|---|
| ln Vitro |
Human cells at rest that have had their cAMP levels inhibited by 100 nM Cl-IB-MECA are countered by MRE3008F20 (0.1-100 nM) [1].
MRE 3008-F20 binds to the human A3 adenosine receptor with Ki of approximately 0.82 nM. It shows high selectivity for A3AR over A1, A2A, and A2B receptors. By antagonizing A3AR, it blocks adenosine-mediated signaling through this receptor, including inhibition of adenylyl cyclase and modulation of various downstream pathways. |
| ln Vivo |
MRE 3008-F20 has been used to elucidate the role of A3 adenosine receptors in various physiological and pathological processes. A3AR antagonists have shown potential in treating inflammatory diseases, cancer, and ischemic conditions. Detailed in vivo activity data are available in primary research publications.
|
| Enzyme Assay |
A3 adenosine receptor binding affinity is measured using radioligand binding assays. Membrane preparations from cells expressing human A3 receptors are incubated with [³H]-MRE 3008-F20 or other radiolabeled A3 ligands and varying concentrations of unlabeled MRE 3008-F20. Specific binding is determined to calculate Ki values.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: human lymphocytes Tested Concentrations: 0.1-100 nM Incubation Duration: Experimental Results: Antagonizes the inhibition of cAMP levels induced by 100 nM Cl-IB-MECA, with an IC50 of 5.0 nM in resting lymphocytes. A3 receptor functional activity is assessed in cells expressing human A3 receptors. Cells are treated with A3 agonists (e.g., Cl-IB-MECA) in the presence or absence of MRE 3008-F20. Downstream signaling (cAMP inhibition, ERK phosphorylation) is measured. IC50 values for antagonism are determined from dose-response curves. |
| Animal Protocol |
MRE 3008-F20 is evaluated in animal models of inflammation, cancer, or ischemic injury. Animals are treated with MRE 3008-F20 via intraperitoneal or oral administration. Disease progression, inflammatory markers, and survival are monitored. A3 receptor occupancy is assessed by ex vivo binding assays.
|
| ADME/Pharmacokinetics |
MRE 3008-F20 has molecular weight and formula available in primary research publications. It is a small-molecule A3 adenosine receptor antagonist suitable for both in vitro and in vivo applications. Detailed pharmacokinetic parameters (half-life, bioavailability, clearance) are available in primary research publications.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity data for MRE 3008-F20 are limited. As an A3 receptor antagonist, it is expected to have a manageable safety profile. Standard toxicological assessments would be required for clinical development.
|
| References |
[1]. Gessi S, et al. Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol. 2004 Mar;65(3):711-9.
[2]. Baraldi P G, et al. New potent and selective human adenosine A3 receptor antagonists. Trends in pharmacological sciences, 2000, 21(12): 456-459. |
| Additional Infomation |
InChIKey: CJRNHKSLHHWUAB-UHFFFAOYSA-N
MRE 3008-F20 is a research tool for studying A3 adenosine receptor biology. Its mechanism involves selective antagonism of the A3 receptor, blocking adenosine-mediated signaling. This compound has been instrumental in defining the role of A3 receptors in various disease models. No clinical trials or approved therapeutic indications exist for this compound. |
| Molecular Formula |
C21H20N8O3
|
|---|---|
| Molecular Weight |
432.44
|
| Exact Mass |
432.166
|
| CAS # |
252979-43-4
|
| PubChem CID |
5310960
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.291
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCN1C=C2C(=N1)N=C(N3C2=NC(=N3)C4=CC=CO4)NC(=O)NC5=CC=C(C=C5)OC
|
| InChi Key |
CJRNHKSLHHWUAB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20N8O3/c1-3-10-28-12-15-17(26-28)24-20(25-21(30)22-13-6-8-14(31-2)9-7-13)29-19(15)23-18(27-29)16-5-4-11-32-16/h4-9,11-12H,3,10H2,1-2H3,(H2,22,24,25,26,30)
|
| Chemical Name |
1-[4-(furan-2-yl)-11-propyl-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-yl]-3-(4-methoxyphenyl)urea
|
| Synonyms |
MRE 3008 F20; MRE 3008F20; MRE 3008-F20
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3125 mL | 11.5623 mL | 23.1246 mL | |
| 5 mM | 0.4625 mL | 2.3125 mL | 4.6249 mL | |
| 10 mM | 0.2312 mL | 1.1562 mL | 2.3125 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
